Skip to main content
Fig. 1 | Molecular Autism

Fig. 1

From: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder

Fig. 1

Study timeline (6 total visits); in Phase 1 (1–15 weeks) participants were randomly assigned to either SF or placebo with visits at baseline, 7 and 15 weeks. In Phase 2 (16–30 weeks), all participants received SF and returned for follow-up at 22 and 30 weeks. In Phase 3 (31–36 weeks), there was no treatment, with a final visit at 36 weeks

Back to article page